Common low-penetrance risk variants associated with breast cancer in Polish women

BMC Cancer

Joanna K Ledwoń⁴  Ewa E Hennig²  Natalia Maryan⁴  Krzysztof Goryca²  Dorota Nowakowska³  Anna Niwińska¹  Jerzy Ostrowski² 

[1] Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

[2] Department of Genetics, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

[3] Genetic Counseling Unit, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

[4] Department of Gastroenterology and Hepatology, Medical Center for Postgraduate Education, Warsaw, Poland

关键词: Genetic associations;    Single nucleotide polymorphism;    Cancer susceptibility;    Breast cancer;   

Others  :  1079484
DOI  :  10.1186/1471-2407-13-510

 received in 2013-04-26, accepted in 2013-10-23,  发布年份 2013

【 摘 要 】

Background

Breast cancer is the most common type of cancer and the second leading cause of cancer-death among women in Poland. The known high-risk mutations account for 25% of familial aggregation cases and 5% of total breast cancer predisposition. Genome-wide association studies have identified a number of common low-penetrance genetic variants, but their contribution to disease risk differs between populations.

Methods

To verify selected associations with breast cancer susceptibility among Polish women, the replication study was performed, included 1424 women with breast cancer and 1788 healthy persons. Sixteen single-nucleotide polymorphisms (SNPs) were analyzed using TaqMan SNP Genotyping Assays. Allele frequency differences were tested using chi²-test implemented in PLINK v1.07 and Cochran-Armitage trend test was performed using R software.

Results

Significant differences (Bonferroni corrected p-value_cor ≤ 0.0197) in the frequency of alleles distribution between all cancer and control subjects were observed for four (rs2736098, rs13281615, rs1219648, rs2981582) out of 16 SNPs. The same result was obtained for group of patients without high-risk BRCA1/2 mutations. The rs1219648 (p-value_cor ≤ 6.73E-03) and rs2981582 (p-value_cor ≤ 6.48E-03) SNPs showed significant association with both familial and sporadic cancers. Additionally, rs2736098 (p-value_cor ≤ 0.0234) was associated with only sporadic cancers; also in group without carriers of high-risk mutation. All these associations revealed their significance also in Cochran-Armitage trend test. Opposite to other SNPs, rs2736098 was associated with a decreased risk of breast cancer.

Conclusion

The association of four known susceptibility SNPs, representing three individual loci, with breast cancer risk in Polish women was confirmed. One of them (rs2736098) seems to be specific for the Polish population. Due to the population differences in allele frequencies, identification of general genetic risk factors requires sets of association studies conducted on different populations.

【 授权许可】

   
2013 Ledwoń et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. http://globocan.iarc.fr/ webcite
• [2]Wojciechowska U, Didkowska J, Zatonski W: Cancer in Poland in 2008. 2010, 1-124. http://onkologia.org.pl/wp-content/uploads/Nowotwory2008.pdf webcite
• [3]Foulkes WD: Inherited susceptibility to common cancers. N Engl J Med 2008, 359:2143-2153.
• [4]Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi O-P, Thompson D, Evans C, Peto J, et al.: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72:1117-1130.
• [5]Metcalfe K, Lubinski J, Lynch HT, Ghadirian P, Foulkes WD, Kim-Sing C, Neuhausen S, Tung N, Rosen B, Gronwald J, Ainsworth P, Sweet K, Eisen A, Sun P, Narod SA, The Hereditary Breast Cancer Clinical Study Group: Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. J Nat Cancer Ins 2010, 102:1874-1878.
• [6]Thompson D, Easton D: The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 2004, 9:221-236.
• [7]Antoniou AC, Easton DF: Models of genetic susceptibility to breast cancer. Oncogene 2006, 25:5898-5905.
• [8]Easton DF, Pooley KA, Dunning AM, Pharoah PDP, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen C-Y, Wu P-E, Wang H-C, Eccles D, Evans DG, Peto J, Fletcher O, et al.: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447:1087-1093.
• [9]Pharoah PDP, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BAJ: Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002, 31:33-36.
• [10]Dai J, Hu Z, Jiang Y, Shen H, Dong J, Ma H, Shen H: Breast cancer risk assessment with five independent genetic variants and two risk factors in Chinese women. Breast cancer research: BCR 2012, 14:R17. BioMed Central Full Text
• [11]Harlid S, Ivarsson MIL, Butt S, Grzybowska E, Eyfjörd JE, Lenner P, Försti A, Hemminki K, Manjer J, Dillner J, Carlson J: Combined effect of low-penetrant SNPs on breast cancer risk. Br J Cancer 2012, 106:389-396.
• [12]Hindorff L, MacArthur J, Morales J, Junkins HA, Hall PN, Klemm AK, Manolio TA: A Catalog of Published Genome-Wide Association Studies. A Catalog of Published Genome-Wide Association Studies. http://www.genome.gov/gwastudies webcite
• [13]Peng S, Lü B, Ruan W, Zhu Y, Sheng H, Lai M: Genetic polymorphisms and breast cancer risk: evidence from meta-analyses, pooled analyses, and genome-wide association studies. Breast Cancer Res Treat 2011, 127:309-324.
• [14]Milne RL, Benítez J, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Arias JI, Zamora MP, Burwinkel B, Bartram CR, Meindl A, Schmutzler RK, Cox A, Brock I, Elliott G, Reed MWR, Southey MC, Smith L, Spurdle AB, Hopper JL, Couch FJ, Olson JE, Wang X, Fredericksen Z, Schürmann P, Bremer M, Hillemanns P, Dörk T, Devilee P, van Asperen CJ, et al.: Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst 2009, 101:1012-1018.
• [15]Zhou P, Du L-F, Lv G-Q, Yu X-M, Gu Y-L, Li J-P, Zhang C: Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2011, 127:813-818.
• [16]Chen M-B, Li C, Shen W-X, Guo Y-J, Shen W, Lu P-H: Association of a LSP1 gene rs3817198T>C polymorphism with breast cancer risk: evidence from 33,920 cases and 35,671 controls. Mol Biol Rep 2011, 38:4687-4695.
• [17]Fletcher O, Johnson N, Gibson L, Coupland B, Fraser A, Leonard A, dos Santos Silva I, Ashworth A, Houlston R, Peto J: Association of genetic variants at 8q24 with breast cancer risk . Cancer Epidemiol Biomarkers Prev 2008, 17:702-705.
• [18]Mcinerney N, Colleran G, Rowan A, Walther A, Barclay E, Spain S, Jones AM, Tuohy S, Curran C, Miller N, Kerin M, Tomlinson I, Sawyer E: Low penetrance breast cancer predisposition SNPs are site specific. Breast Cancer Res Treat 2009, 117:151-159.
• [19]Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H, Heikkinen T, Simard J, Spurdle AB, Beesley J, Chen X, Neuhausen SL, Ding YC, Couch FJ, Wang X, Fredericksen Z, Peterlongo P, Peissel B, Bonanni B, Viel A, Bernard L, Radice P, Szabo CI, Foretova L, Zikan M, Claes K, Greene MH, Mai PL, Rennert G, Lejbkowicz F, Andrulis IL, et al.: Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2009, 18:4442-4456.
• [20]Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, Seal S, Ghoussaini M, Hines S, Healey CS, Hughes D, Warren-Perry M, Tapper W, Eccles D, Evans DG, Hooning M, Schutte M, van den Ouweland A, Houlston R, Ross G, Langford C, Pharoah PDP, Stratton MR, Dunning AM, Rahman N, Easton DF: Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 2010, 42:504-507.
• [21]Li J, Humphreys K, Heikkinen T, Aittomäki K, Blomqvist C, Pharoah PDP, Dunning AM, Ahmed S, Hooning MJ, Martens JWM, Ouweland AMW, Alfredsson L, Palotie A, Peltonen-Palotie L, Irwanto A, Low HQ, Teoh GHK, Thalamuthu A, Easton DF, Nevanlinna H, Liu J, Czene K, Hall P: A combined analysis of genome-wide association studies in breast cancer. Breast Cancer Res Treat 2010, 126:717-727.
• [22]Fletcher O, Johnson N, Orr N, Hosking FJ, Gibson LJ, Walker K, Zelenika D, Gut I, Heath S, Palles C, Coupland B, Broderick P, Schoemaker M, Jones M, Williamson J, Chilcott-Burns S, Tomczyk K, Simpson G, Jacobs KB, Chanock SJ, Hunter DJ, Tomlinson IP, Swerdlow A, Ashworth A, Ross G, Dos Santos Silva I, Lathrop M, Houlston RS, Peto J: Novel Breast Cancer Susceptibility Locus at 9q31.2: Results of a Genome-Wide Association Study. J Nat Cancer Inst 2011, 103:425-435.
• [23]Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS, Apicella C, Smith LD, Hammet F, Southey MC, Veer LJV'T, De GR, Smit VTHBM, Fasching PA, Beckmann MW, Jud S, Ekici AB, Hartmann A, Hein A, Schulz-Wendtland R, Burwinkel B, Marme F, Schneeweiss A, Sinn H-P, Sohn C, Tchatchou S, Bojesen SE, Nordestgaard BG, Flyger H, Ørsted DD, et al.: Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet 2011, 20:3289-3303.
• [24]Zhang B, Beeghly-Fadiel A, Long J, Zheng W: Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol 2011, 12:477-488.
• [25]Jostins L, Barrett JC: Genetic risk prediction in complex disease. Hum Mol Genet 2011, 20:R182-R188.
• [26]Brozek I, Cybulska C, Ratajska M, Piatkowska M, Kluska A, Balabas A, Dabrowska M, Nowakowska D, Niwinska A, Pamula-Pilat J, Tecza K, Pekala W, Rembowska J, Nowicka K, Mosor M, Januszkiewicz-Lewandowska D, Rachtan J, Grzybowska E, Nowak J, Steffen J, Limon J: Prevalence of the most frequent BRCA1 mutations in Polish population. J Appl Genet 2011, 52:325-330.
• [27]Górski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, Mackiewicz A, Stawicka M, Bebenek M, Sorokin D, Fiszer-Maliszewska Ł, Haus O, Janiszewska H, Niepsuj S, Góźdź S, Zaremba L, Posmyk M, Płuzańska M, Kilar E, Czudowska D, Waśko B, Miturski R, Kowalczyk JR, Urbański K, Szwiec M, Koc J, Debniak B, Rozmiarek A, Debniak T, Cybulski C, et al.: A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 2004, 110:683-686.
• [28]Gaj P, Kluska A, Nowakowska D, Bałabas A, Piątkowska M, Dabrowska M, Niwińska A, Ostrowski J: High frequency of BRCA1 founder mutations in Polish women with nonfamilial breast cancer. Fam Cancer 2012, 11:623-628.
• [29]Beeghly-Fadiel A, Lu W, Long J-R, Shu X, Zheng Y, Cai Q, Gao Y-T, Zheng W: Matrix Metalloproteinase-2 Polymorphisms and Breast Cancer Susceptibility. Cancer Epidemiol Biomarkers Prev 2009, 18:1770-1776.
• [30]Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover RN, Thomas G, Chanock SJ: A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007, 39:870-874.
• [31]Savage SA, Chanock SJ, Lissowska J, Brinton LA, Richesson D, Peplonska B, Bardin-Mikolajczak A, Zatonski W, Szeszenia-Dabrowska N, Garcia-Closas M: Genetic variation in five genes important in telomere biology and risk for breast cancer. Br J Cancer 2007, 97:832-836.
• [32]Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, Gudjonsson SA, Masson G, Jakobsdottir M, Thorlacius S, Helgason A, Aben KK, Strobbe LJ, Albers-Akkers MT, Swinkels DW, Henderson BE, Kolonel LN, Le Marchand L, Millastre E, Andres R, Godino J, Garcia-Prats MD, Polo E, Tres A, Mouy M, Saemundsdottir J, Backman VM, Gudmundsson L, Kristjansson K, Bergthorsson JT, Kostic J, et al.: Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2007, 39:865-869.
• [33]Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, Hankinson SE, Hutchinson A, Wang Z, Yu K, Chatterjee N, Garcia-Closas M, Gonzalez-Bosquet J, Prokunina-Olsson L, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Diver R, Prentice R, Jackson R, Kooperberg C, Chlebowski R, Lissowska J, et al.: A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 2009, 41:579-584.
• [34]Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, Jonsson GF, Jakobsdottir M, Bergthorsson JT, Gudmundsson J, Aben KK, Strobbe LJ, Swinkels DW, van Engelenburg KCA, Henderson BE, Kolonel LN, Le Marchand L, Millastre E, Andres R, Saez B, Lambea J, Godino J, Polo E, Tres A, Picelli S, Rantala J, Margolin S, Jonsson T, Sigurdsson H, Jonsdottir T, Hrafnkelsson J, et al.: Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2008, 40:703-706.
• [35]Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MWR, Pooley KA, Scollen S, Baynes C, Ponder BAJ, Chanock S, Lissowska J, Brinton L, Peplonska B, Southey MC, Hopper JL, McCredie MRE, Giles GG, Fletcher O, Johnson N, dos Santos SI, Gibson L, Bojesen SE, Nordestgaard BG, Axelsson CK, Torres D, Hamann U, Justenhoven C, Brauch H, Chang-Claude J, Kropp S, et al.: A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007, 39:352-358.
• [36]Loizidou MA, Michael T, Neuhausen SL, Newbold RF, Marcou Y, Kakouri E, Daniel M, Papadopoulos P, Malas S, Hadjisavvas A, Kyriacou K: DNA-repair genetic polymorphisms and risk of breast cancer in Cyprus. Breast Cancer Res Treat 2008, 115:623-627.
• [37]Debniak T, Górski B, Huzarski T, Byrski T, Cybulski C, Mackiewicz A, Gozdecka-Grodecka S, Gronwald J, Kowalska E, Haus O, Grzybowska E, Stawicka M, Swiec M, Urbański K, Niepsuj S, Waśko B, Góźdź S, Wandzel P, Szczylik C, Surdyka D, Rozmiarek A, Zambrano O, Posmyk M, Narod SA, Lubinski J: A common variant of CDKN2A (p16) predisposes to breast cancer. J Med Genet 2005, 42:763-765.
• [38]Ghoussaini M, Song H, Koessler T, Al Olama AA, Kote-Jarai Z, Driver KE, Pooley KA, Ramus SJ, Kjaer SK, Hogdall E, DiCioccio RA, Whittemore AS, Gayther SA, Giles GG, Guy M, Edwards SM, Morrison J, Donovan JL, Hamdy FC, Dearnaley DP, Ardern-Jones AT, Hall AL, O’Brien LT, Gehr-Swain BN, Wilkinson RA, Brown PM, Hopper JL, Neal DE, Pharoah PDP, Ponder BAJ, et al.: Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst 2008, 100:962-966.
• [39]Johnson AD, Handsaker RE, Pulit S, Nizzari MM, O’Donnell CJ, de Bakker PIW: SNAP: A web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008, 24(24):2938-2939.
• [40]Pharoah PDP, Antoniou AC, Easton DF, Ponder BAJ: Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008, 358:2796-2803.
• [41]Milne RL, Antoniou AC: Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers. Ann Oncol 2011, 22(Suppl 1):i11-i17.
• [42]Eswarakumar VP, Lax I, Schlessinger J: Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005, 16:139-149.
• [43]Koziczak M, Holbro T, Hynes NE: Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 2004, 23:3501-3508.
• [44]Adnane J, Gaudray P, Dionne CA, Crumley G, Jaye M, Schlessinger J, Jeanteur P, Birnbaum D, Theillet C: BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene 1991, 6:659-663.
• [45]Tannheimer SL, Rehemtulla A, Ethier SP: Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res 2000, 2:311-320. BioMed Central Full Text
• [46]Huijts PEA, Vreeswijk MPG, Kroeze-Jansema KHG, Jacobi CE, Seynaeve C, Krol-Warmerdam EMM, Wijers-Koster PM, Blom JC, Pooley KA, Klijn JGM, Tollenaar RAEM, Devilee P, van Asperen CJ: Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Breast Cancer Res 2007, 9:R78. BioMed Central Full Text
• [47]Jara L, Gonzalez-Hormazabal P, Cerceño K, Di Capua GA, Reyes JM, Blanco R, Bravo T, Peralta O, Gomez F, Waugh E, Margarit S, Ibañez G, Romero C, Pakomio J, Roizen G: Genetic variants in FGFR2 and MAP3K1 are associated with the risk of familial and early-onset breast cancer in a South-American population. Breast Cancer Res Treat 2013, 137:559-569.
• [48]Latif A, Hadfield KD, Roberts SA, Shenton A, Lalloo F, Black GCM, Howell A, Evans DG, Newman WG: Breast cancer susceptibility variants alter risks in familial disease. J Med Genet 2010, 47:126-131.
• [49]Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs C, Ganz PA, Tomlinson G, Olopade OI, Couch FJ, Wang X, Lindor NM, Pankratz VS, Radice P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Viel A, Allavena A, Dall’Olio V, Peterlongo P, Szabo CI, Zikan M, Claes K, et al.: Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res 2010, 70:9742-9754.
• [50]Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Hofmann W, Sutter C, Niederacher D, Deissler H, Caldes T, Kämpjärvi K, Nevanlinna H, Simard J, Beesley J, Chen X, Neuhausen SL, Rebbeck TR, Wagner T, Lynch HT, Isaacs C, Weitzel J, Ganz PA, Daly MB, Tomlinson G, Olopade OI, et al.: Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008, 82:937-948.
• [51]Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002, 20:2310-2318.
• [52]Meyer KB, Maia A-T, O’Reilly M, Teschendorff AE, Chin S-F, Caldas C, Ponder BAJ: Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol 2008, 6:e108.
• [53]Sun C, Olopade OI, Di Rienzo A: rs2981582 is associated with FGFR2 expression in normal breast. Cancer Genet Cytogenet 2010, 197:193-194.
• [54]Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, Leongamornlert DA, Tymrakiewicz M, Jhavar S, Saunders E, Hopper JL, Southey MC, Muir KR, English DR, Dearnaley DP, Ardern-Jones AT, Hall AL, O’Brien LT, Wilkinson RA, Sawyer E, Lophatananon A, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper C, et al.: Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 2009, 41:1058-1060.
• [55]Sotelo J, Esposito D, Duhagon MA, Banfield K, Mehalko J, Liao H, Stephens RM, Harris TJR, Munroe DJ, Wu X: Long-range enhancers on 8q24 regulate c-Myc. Proc Natl Acad Sci U S A 2010, 107:3001-3005.
• [56]Liao DJ, Dickson RB: c-Myc in breast cancer. Endocr Relat Cancer 2000, 7:143-164.
• [57]Wang Y, Liu S, Zhang G, Zhou C, Zhu H, Zhou X, Quan L, Bai J, Xu N: Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res 2005, 7:R220-R228. BioMed Central Full Text
• [58]Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, Ribas G, González-Neira A, Benítez J, Zamora P, Brauch H, Justenhoven C, Hamann U, Ko Y-D, Bruening T, Haas S, Dörk T, Schürmann P, Hillemanns P, Bogdanova N, Bremer M, Karstens JH, Fagerholm R, Aaltonen K, Aittomäki K, et al.: Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008, 4:e1000054.
• [59]Rafnar T, Sulem P, Stacey SN, Geller F, Gudmundsson J, Sigurdsson A, Jakobsdottir M, Helgadottir H, Thorlacius S, Aben KKH, Blöndal T, Thorgeirsson TE, Thorleifsson G, Kristjansson K, Thorisdottir K, Ragnarsson R, Sigurgeirsson B, Skuladottir H, Gudbjartsson T, Isaksson HJ, Einarsson GV, Benediktsdottir KR, Agnarsson BA, Olafsson K, Salvarsdottir A, Bjarnason H, Asgeirsdottir M, Kristinsson KT, Matthiasdottir S, Sveinsdottir SG, et al.: Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 2009, 41:221-227.
• [60]Mocellin S, Verdi D, Pooley KA, Landi MT, Egan KM, Baird DM, Prescott J, De Vivo I, Nitti D: Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis. J Natl Cancer Inst 2012, 104:840-854.
• [61]Zhang X-J, Xu Z, Gong Y-L, Tang C-J, Chen J-F: Association of TERT rs2736098 polymorphism with cancer risk: a meta-analysis. Asian Pac J Cancer Prev 2012, 13:4943-4946.
• [62]Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, Wang X, Ademuyiwa F, Ahmed S, Ambrosone CB, Baglietto L, Balleine R, Bandera EV, Beckmann MW, Berg CD, Bernstein L, Blomqvist C, Blot WJ, Brauch H, Buring JE, Carey LA, Carpenter JE, Chang-Claude J, Chanock SJ, Chasman DI, Clarke CL, Cox A, Cross SS, Deming SL, Diasio RB, et al.: A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet 2011, 43:1210-1214.
• [63]Blackburn EH: Switching and signaling at the telomere. Cell 2001, 106:661-673.
• [64]Liu Z, Li G, Wei S, Niu J, Wang L-E, Sturgis EM, Wei Q: Genetic variations in TERT-CLPTM1L genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis 2010, 31:1977-1981.
• [65]Hsu C-P, Hsu N-Y, Lee L-W, Ko J-L: Ets2 binding site single nucleotide polymorphism at the hTERT gene promoter–effect on telomerase expression and telomere length maintenance in non-small cell lung cancer. Eur J Cancer 2006, 42:1466-1474.